Inspired by patients to challenge the status quo
Olema is committed to partnering with patients to develop new, effective therapies for women’s cancers.
We refuse to accept the current standard of care as the best-case scenario for women living with cancer and are optimistic that we can deliver a potential new solution. Across our company and in all we do, Olema is relentlessly focused on creating a better way.
Our Science
Current Clinical Trials
Study Details | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | ClinicalTrials.gov | OPERA-01
Please click here to view the trial details on ClinicalTrials.gov
(For US Audiences Only) OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)
Please visit OPERA01study.com for more information about participation in the trial.
A Phase 1b Study in Combination With a CDK4/6 Inhibitor or With a PI3K Inhibitor
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients